Equatorial Guinea (EG) Ministry of Health meets in Washington,DC with GB Group Global andTNI Biotech (OTCBB:TNIB) to launch major innovative health solutions and improve pharmaceutical quality for its citizens.
Washington, D.C. The EG Ministry of Health met with Dr. Gloria B. Herndon of GB Group Global in the nation’s capital recently as part of Equitorial Guinea’s efforts to dramatically raise its standards of health care. These endeavors include building a pharmaceutical manufacturing facility in EG, implementing pharmaceutical quality control and policies, and exploring the release of a new treatment (Low Dose Naltrexone LDN) against cancer and HIV/AIDS.
The purpose of the visit of Dr. Diosdado-Vicente Milang Nsue, the Delegate Minister of Health & Social Services and Dr. Consuelo Ondo Efua the D i r e c t 
o r G e n e r a l o f Drug Supply and Medical Equipment, was to engage with organizations who through assistance, partnership and the sharing of best practices could close knowledge gaps and help bring improved health care to Equatorial Guineans. The visitors’ meetings with members of the medical community were facilitated by Dr. Herndon, President and Managing Member of GB Group Global andits wide ranging auxiliary companies, GB Energie, GB Pharma and GB Oncology and Imaging Group.
Presiding over their near week-long stay, Dr. Herndon said the government of EG had included the improvement of health care as a facet of the “Industrialization Plan-2020”, which was defined by the government and stretches across all sectors of the country to focus on raising the economic level and quality of life of the country’s citizens by year 2020.
Among issues discussed, Minister Dr. Milang Nsue raised a problem rampant overseas: The need for affordable high quality medicines. “The devastating effects of substandard and counterfeit medicines in circulation lead to treatment failure, increased mortality; and the development of drug resistance.” Dr. Milang Nsue also stressed that “…establishing in Equatorial Africa a pharmaceutical manufacturing facility with an analytical laboratory would be of paramount importance.” The proposed facility was part of conversations with TNI Bio Tech Inc., GB Pharma, Gb Oncology & Imaging Group, Howard University and the United States Pharmacopeia (USP) representatives, with whom partnerships were discussed.
The Director of Pharmacology, Dr. Ondo Efua said “With the availability of a drug manufacturing facility to treat the most current pathologies, we could secure the safety and high quality of medicines either produced in EG or imported. We would have taken an important step to halt the traffic and commercialization of the counterfeit medicines that undermine the quality of the health services delivered to our population” Further, as EG is concerned with the global struggle to combat the scourge of diseases such as HIV/AIDS and cancer, new developments regarding the therapy known asIRT-103 Low Dose Naltrexone* (LDN) were explained during the sessions with TNI Bio Tech Inc. (OTCBB:TNIB) IRT-103 is an active immunotherapy for patients with deficient functioning of the immune system. It works within the body by activating the patient’s immune system to attack and destroy cancer cells and controlling infectious diseases such as HIV/AIDS. The therapy has been hailed in other countries where it will be used as inexpensive and simple to manage, requiring only one dose each day, taken orally.
The process to initiate approval of the treatment of HIV/AIDS and cancer by IRT-103 should begin soon. This step will change the lives of the country’s citizens, by decreasing the sufferings and death of the killer diseases, and will permit Equatorial Guinea to take a leadership position in eliminating these plagues. A meeting will be held in Malabo, the capital of Equatorial Guinea, with the technical team of TNIB, GB Pharma and GB Oncology & Imaging Group in order to present the significance of IRT-103 to the medical and scientific community of EG and acquainting them with IRT-103’s most recent advances and widened scope. Concluding the sessions, Dr. Herndon said she felt the exchanges had been productive, and was pleased that “…we (GB Group Global) were able to demonstrate our commitment to viable and sustainable solutions to the issues of the citizens well being and the growth of the nation.”
GB Group Global’s entrepreneurial founder, Dr. Gloria B. Herndon, has more than 35 years of successfully conducting business internationally. Her social give-back programs in education, healthcare and municipal development are just a few areas the GB Group champions together with its collateral partners. The GB Group currently focuses on innovative and sustainable solutions in the energy, environment and health sectors.
GB Group Global
providing innovative & sustainable solutions while doing good
MEDIA CONTACT:
Jan Du Plain
202-486-7004
